Class action lawsuit filed against uniQure N.V. (QURE) for securities fraud by Kessler Topaz Meltzer

uniQure N.V. (QURE) is currently facing a securities fraud class action lawsuit filed by Kessler Topaz Meltzer & Check, LLP. This lawsuit alleges that uniQure made material misstatements and omissions regarding its Huntington’s disease gene therapy drug between September 24, 2025, and October 31, 2025. Investors who purchased or acquired uniQure ordinary shares during this period have until April 13, 2026, to seek lead plaintiff status in this case.

During the Class Period, uniQure, a biotechnology company specializing in gene therapies for rare diseases, including Huntington’s disease, was accused of misleading investors about its Phase I/II clinical trials of AMT-130 and the timeline for submitting its Biologics License Application (BLA) to the FDA for approval. The lawsuit alleges that uniQure’s statements regarding its Pivotal Study, including comparing the results to an external data set, were not fully approved by the FDA. Additionally, uniQure downplayed the need for additional studies to complement its BLA submission despite successful Pivotal Study results, leading to a lack of a reasonable basis for its statements on business operations and prospects.

The truth about uniQure’s prospects emerged on November 3, 2025, when the company disclosed that the FDA no longer believed that the data from the Phase I/II studies of AMT-130 were adequate to support a BLA submission. This revelation caused uniQure’s ordinary shares to drop significantly by over 49%, from $67.69 to $34.29 per share. As a result, investors suffered substantial losses due to the company’s alleged misleading statements and withheld information.

Investors who feel they have been affected by uniQure’s actions are encouraged to file for lead plaintiff status by April 13, 2026, and reach out to Kessler Topaz Meltzer & Check, LLP for a free case evaluation. By taking action, investors can actively participate in the legal process and potentially recover losses resulting from uniQure’s alleged securities fraud. It is essential for investors to understand their rights and options moving forward to protect their investments and seek potential remedies for damages incurred.

In conclusion, the securities fraud class action lawsuit against uniQure N.V. serves as a reminder of the importance of transparency and accuracy in business operations. Investors have a right to truthful information to make informed decisions about their investments, and companies must uphold their responsibility to provide accurate and reliable data to stakeholders. By holding companies accountable for their actions, investors can help maintain integrity and trust within the financial markets.